In vitro activity and in vivo efficacy of tigecycline alone and in combination with daptomycin and rifampin against Gram-positive cocci isolated from surgical wound infection

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 8, 2012, Pages 1759-1764

  Silvestri, C ^a   Cirioni, O ^a,c   Arzeni, D ^a   Ghiselli, R ^a   Simonetti, O ^a   Orlando, F ^b   Ganzetti, G ^a   Staffolani, S ^a   Brescini, L ^a   Provinciali, M ^b   Offidani, A ^a   Guerrieri, M ^a   Giacometti, A ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b INRCA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN; IMIPENEM; LEVOFLOXACIN; RIFAMPICIN; TEICOPLANIN; TIGECYCLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BAGG ALBINO MOUSE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCOCCUS FAECALIS; GRAM POSITIVE COCCI; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; DAPTOMYCIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GRAM-POSITIVE BACTERIAL INFECTIONS; GRAM-POSITIVE COCCI; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; RIFAMPIN; SURGICAL WOUND INFECTION; TREATMENT OUTCOME;

EID: 84866393193     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1498-1     Document Type: Article

References (29)

1. Cormican MG, Jones RN (1996) Emerging resistance to antimicrobial agents in Gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci. Drugs 51:S6- S12
2. Linden PK (1998) Clinical implications of nosocomial grampositive bacteremia and superimposed antimicrobial resistance. Am J Med 104:24S-33S (Pubitemid 28299975)
3. Bratzler DW, Houck PM; Surgical Infection Prevention Guidelines Writers Workgroup et al (2004) Antimicrobial prophylaxis for surgery: an advisory statement from the National Surgical Infection Prevention Project. Clin Infect Dis 38:1706-1715 (Pubitemid 38781662)
4. Burke JP (2003) Infection control - a problem for patient safety. N Engl J Med 348:651-656 (Pubitemid 36204961)
5. Hirsch T, Koerber A, Jacobsen F et al (2010) Evaluation of toxic side effects of clinically used skin antiseptics in vitro. J Surg Res 164:344-350
6. El-Azizi M, Rao S, Kanchanapoom T et al (2005) In vitro activity of vancomycin, quinupristin/dalfopristin, and linezolid against intact and disrupted biofilms of staphylococci. Ann Clin Microbiol Antimicrob 4:2
7. Lode HM (2009) Clinical impact of antibiotic-resistant Grampositive pathogens. Clin Microbiol Infect 15:212-217
8. Bouza E (2009) New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 15(Suppl 7):44-52
9. Moellering RC Jr (1998) Problems with antimicrobial resistance in gram-positive cocci. Clin Infect Dis 26:1177-1178 (Pubitemid 28215484)
10. Arias CA, Contreras GA, Murray BE (2010) Management of multidrug-resistant enterococcal infections. Clin Microbiol Infect 16:555-562
11. Diekema DJ, BootsMiller BJ, Vaughn TE et al (2004) Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38:78-85 (Pubitemid 38045876)
12. Giacometti A, Cirioni O, Kamysz W et al (2005) In vitro activity and killing effect of temporin A on nosocomial isolates of Enterococcus faecalis and interactions with clinically used antibiotics. J Antimicrob Chemother 55:272-274 (Pubitemid 40331159)
13. Spellberg B, Guidos R, Gilbert D et al (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164 (Pubitemid 351269151)
14. Montefour K, Frieden J, Hurst S et al (2008) Acinetobacter baumannii: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse 28:15-25
15. Labthavikul P, Petersen PJ, Bradford PA (2003) In vitro activity of tigecycline against Staphylococcus epidermidis growing in an adherent-cell biofilm model. Antimicrob Agents Chemother 47:3967-3969 (Pubitemid 37485017)
16. Clinical and Laboratory Standards Institute (CLSI) (2003) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. National Committee for Clinical Laboratory Standards (NCCLS), Villanova, PA
17. Petersen PJ, Labthavikul P, Jones CH (2006) In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 57:573-576 (Pubitemid 43240214)
18. Rand KH, Houck HJ, Brown P et al (1993) Reproducibility of the microdilution checkerboard method for antibiotic synergy. Antimicrob Agents Chemother 37:613-615 (Pubitemid 23072613)
19. Simonetti O, Cirioni O, Ghiselli R et al (2008) RNAIII-inhibiting peptide enhances healing of wounds infected with methicillinresistant Staphylococcus aureus. Antimicrob Agents Chemother 52:2205-2211 (Pubitemid 351758560)
20. Kugelberg E, Norström T, Petersen TK et al (2005) Establishment of a superficial skin infection model in mice by using Staphylococcus aureus and Streptococcus pyogenes. Antimicrob Agents Chemother 49:3435-3441 (Pubitemid 41060593)
21. Lin MY, Hayden MK (2010) Methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus: recognition and prevention in intensive care units. Crit Care Med 38:S335-S344
22. Peterson LR (2008) A review of tigecycline - the first glycylcycline. Int J Antimicrob Agents 32:S215-S222
23. Hoban DJ, Bouchillon SK, Johnson BM et al; Tigecycline Evaluation and Surveillance trial (TEST Program) Group (2005) In vitro activity of tigecycline against 6792 Gram-negative and Grampositive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004). Diagn Microbiol Infect Dis 52:215-227 (Pubitemid 41133548)
24. Moland ES, Craft DW, Hong SG et al (2008) In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy. Antimicrob Agents Chemother 52:2940-2942
25. Rathe M, Kristensen L, Ellermann-Eriksen S et al (2010) Vancomycin-resistant Enterococcus spp.: validation of susceptibility testing and in vitro activity of vancomycin, linezolid, tigecycline and daptomycin. APMIS 118:66-73
26. Farrell DJ, Turnidge JD, Bell J et al (2010) The in vitro evaluation of tigecycline tested against pathogens isolated in eight countries in the Asia-Western Pacific region (2008). J Infect 60:440-451
27. Ippolito G, Leone S, Lauria FN et al (2010) Methicillin-resistant Staphylococcus aureus: the superbug. Int J Infect Dis 14(Suppl 4): S7-S11
28. Entenza JM, Moreillon P (2009) Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 34:8.e1-8.e9
29. Rybak MJ, McGrath BJ (1996) Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. Drugs 52:390- 405 (Pubitemid 26293863)